LBL Biotech is developing a combination therapy treatment targeting pancreatic cancer. Our proprietary technology combines IL-20 antibody with an immune checkpoint PD-1 antibody to attenuate tumors and has delivered excellent efficacy in treating liver cancer, breast cancer, cancer-induced cachexia (CAC), chemotherapy-induced neurological disease, and spinal cord injuries.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Taiwan, Tw
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.lblbio.com
- HQ
- Taiwan
Lbl Biotech Questions
Lbl Biotech's website is http://www.lblbio.com
Lbl Biotech's LinkedIn profile is https://tw.linkedin.com/company/lbl-biotech
Lbl Biotech has
1 employees.
View email and phone details for 1
employees at Lbl Biotech.
Lbl Biotech's industry is
Biotechnology Research
Lbl Biotech's top competitors are
Cellusion Inc.,
Ammax Bio., Inc.,
Dotbio,
Apeximmune Therapeutics,
Help Therapeutics,
Onward Therapeutics,
United Immunity, Co., Ltd.,
Hanchorbio Inc. 漢康生技股份有限公司,
Mxt Biotech,
Cyto-Facto Inc..
Lbl Biotech's categories are Biotechnology Research
Lbl Biotech's founding year is 2019
